{"id":"NCT04516746","sponsor":"AstraZeneca","briefTitle":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-28","primaryCompletion":"2021-03-05","completion":"2023-02-10","firstPosted":"2020-08-18","resultsPosted":"2022-04-01","lastUpdate":"2024-02-05"},"enrollment":32450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19","SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"AZD1222","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"AZD1222","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.","primaryOutcome":{"measure":"Number of Participants With Binary Response","timeFrame":"From 15 days post second dose up to data cut-off date (DCO) of 05 March 2021 or study discontinuation or unblinding or receipt of non-study COVID-19 vaccination, up to a maximum of 17 weeks","effectByArm":[{"arm":"AZD1222","deltaMin":73,"sd":null},{"arm":"Placebo","deltaMin":130,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":84,"countries":["United States","Chile","Peru"]},"refs":{"pmids":["32325038","27578435","32007145","27371814","32015507","15033648","39225478","38643547","37385888","36713413","36610390","36106642","34587382"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8110C00001&amp;attachmentIdentifier=58e8ea47-f2dc-4d66-bdba-535e1b50a3a3&amp;fileName=D8110C00001_SAP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8110C00001&amp;attachmentIdentifier=90924b91-95c6-4d19-94f1-d5e77e059c8d&amp;fileName=D8110C00001_CSP_Amendment_6_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8110C00001&amp;attachmentIdentifier=a07258a5-fe26-409c-a940-ae25552c538b&amp;fileName=D8110C00001_Clinical_Study_Report_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1039,"n":21587},"commonTop":["COVID-19","Headache","Injection site pain","Fatigue","Chills"]}}